---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Sep 28, 2008 at 4:45 AM
Subject: Pre- and post-natal treatment of hemophagocytic lymphohistiocytosis.
To: mesothelioma77@gmail.com
[1]Pediatr Blood Cancer. 2008 Sep 25;
Shah AJ, Kapoor N, Cooper RM, Crooks GM, Lenarsky C, Abdel-Azim H, Wu SQ, Wilson K, Weinberg KI, Parkman R, Kohn DB
Hemophagocytic lymphohistiocytosis (HLH) is a rare autosomal recessive disorder of infancy and childhood that is invariably fatal if not treated. We report on the first patient to receive post-natal HSCT for HLH after receiving in utero chemotherapy for disease stabilization. Pediatr Blood Cancer (c) 2008 Wiley-Liss, Inc.
___
Source: http://www.hubmed.org/display.cgi?uids=18819128
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Sep 28, 2008 at 4:45 AM
Subject: Pre- and post-natal treatment of hemophagocytic lymphohistiocytosis.
To: mesothelioma77@gmail.com
[1]Pediatr Blood Cancer. 2008 Sep 25;
Shah AJ, Kapoor N, Cooper RM, Crooks GM, Lenarsky C, Abdel-Azim H, Wu SQ, Wilson K, Weinberg KI, Parkman R, Kohn DB
Hemophagocytic lymphohistiocytosis (HLH) is a rare autosomal recessive disorder of infancy and childhood that is invariably fatal if not treated. We report on the first patient to receive post-natal HSCT for HLH after receiving in utero chemotherapy for disease stabilization. Pediatr Blood Cancer (c) 2008 Wiley-Liss, Inc.
___
Source: http://www.hubmed.org/display.cgi?uids=18819128
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc